Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide for alcohol reduction in schizophrenia with alcohol use disorder
2024-518608-28-00Phase 2Authorised
- Sponsor
- Capital Region of Denmark
- Start
- May 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in alcohol use disorder (AUD) and schizophrenia comparing Tirzepatide arm with Placebo arm (2 arms). Primary endpoint: Percent change in heavy drinking days at 16 weeks. Planned start May 2025; status: authorised.
02
Drugs
03
Conditions
alcohol use disorder (AUD)schizophrenia
Beyond the preview
Go deeper on 2024-518608-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518608-28-00.